Source comparison
Sermorelin Help Body Composition Research: Full Comparison
This table compares sermorelin to alternative interventions used in body composition research. Each row represents a distinct mechanism and evidence profile. | Intervention | Mechanism | Evidence Quality | Lean Mass Gain (12–24 weeks) | Fat Mass Reduction | Su
This comparison does not assign a generated winner or score.
- This table compares sermorelin to alternative interventions used in body composition research. Each row represents a distinct mechanism and evidence profile.
- | Intervention | Mechanism | Evidence Quality | Lean Mass Gain (12–24 weeks) | Fat Mass Reduction | Sustainability After Discontinuation | Professional Assessment ||—|—|—|—|—|—|| Sermorelin 200–500mcg nightly | GHRH receptor agonist → pulsatile endogenous GH release → IGF-1 elevation | Multiple RCTs with DEXA endpoints | 1.5–3kg mean gain | 4–8% reduction in body fat percentage | Moderate. IGF-1 returns to baseline within 4–6 weeks; lean mass partially retained if training continues | Best option for modeling physiological GH restoration without receptor desensitization. Pulsatile secretion preserves feedback loops || Exogenous GH 2–4 IU daily | Direct GH receptor binding → continuous supraphysiological GH levels | Extensive clinical data, primarily from GH deficiency trials | 2–4kg mean gain (dose-dependent) | 6–12% reduction | Low. Endogenous GH production suppressed; rapid lean mass loss upon cessation | More potent acutely but suppresses pituitary function; not suitable for studyin